Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

While the benefits of drug-eluting stents (DES) in low-risk populations are well established, there is ongoing debate about their role in the higher risk setting of acute ST elevation myocardial infarction. This was in response to early studies, which investigated the first generation of DES, demonstrating increased occurrence of very late stent thrombosis. However, more potent antiplatelet agents, novel antithrombotic agents and evolution of DES design and polymers have reduced the occurrence of very late stent thrombosis. Studies evaluating shorter duration of dual antiplatelet therapy following the use of DES are currently underway. This review examines the releVant literature and analyzes the safety and efficacy of implanting DES in patients with ST elevation myocardial infarction. © 2012 Future Medicine Ltd.

Original publication




Journal article


Interventional Cardiology (London)

Publication Date





689 - 700